BioNTech SE (22UAy)

123.40
+0.70(+0.57%)
  • Volume:
    82,044
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    122.60 - 128.50
  • Type:Equity
  • Market:Germany
  • ISIN:US09075V1026
  • WKN:A2PSR2

22UAy Overview

Prev. Close
122.7
Day's Range
122.6-128.5
Revenue
-
Open
125.5
52 wk Range
111.3-395
EPS
-
Volume
82,044
Market Cap
30.86B
Dividend (Yield)
1.5498
(1.19%)
Average Volume (3m)
107,459
P/E Ratio
2.68
Beta
-
1-Year Change
-35.76%
Shares Outstanding
243,019,216
Next Earnings Date
Aug 08, 2022
What is your sentiment on BioNTech?
or
Market is currently closed. Voting is open during market hours.

BioNTech SE Analysis

BioNTech SE Company Profile

BioNTech SE Company Profile

Employees
3082

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellSellSell
Technical IndicatorsStrong SellStrong SellBuyStrong SellSell
SummaryStrong SellStrong SellNeutralStrong SellSell
  • best time to buy before earning report
    0
    • Will continue to rise! Not just pandemic time! No doubt:)
      0
      • End of Pandemic, BNTX stock will be still very promising. Not just for today!
        0
        • Time to buy more. Best choice, approval one!
          0
          • BioNTech&Pfizer: The Best stock to buy right now. Will go up no doubth.
            0
        • Should be strong buy!
          0
          • Pfizer & BioNTech Got 'Full FDA Approval' For Its COVID Vaccine
            0
            • This is criminal!
              0
              • Wtf
                0
                • Analyst target $115
                  0
                  • Time to get back to 31 i guess
                    3